Eric S. White

University of Cambridge — United Kingdom

Medicine · Health Sciences

76h-index20.0kcitations285works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(139), Medical Imaging and Pathology Studies(34), Sarcoidosis and Beryllium Toxicity Research(29), Pulmonary Hypertension Research and Treatments(24), Neonatal Respiratory Health Research(23)

Publications283 total

Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer
Nature Cell Biology·2025· 9 citedOpen Access
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine·2025· 3 cited
Effect of Nintedanib on Quantitative CT in Patients With Progressive Pulmonary Fibrosis: Results from the INBUILD Trial
American Journal of Respiratory and Critical Care Medicine·2025
Baseline Quantitative CT Predicts Rate of Decline in Forced Vital Capacity and Clinically Relevant Outcomes in Patients With Progressive Pulmonary Fibrosis: Results from the INBUILD Trial
American Journal of Respiratory and Critical Care Medicine·2025
Contrasting responses of control and fibrotic lung fibroblasts to fibrotic stimuli: the role of osteoprotegerin in extracellular matrix remodeling
2025· 1 citedOpen Access
A Systematic review of the prevalence of degenerative thoracic spinal pathologies on magnetic resonance imaging in healthy/asymptomatic individuals
Brain and Spine·2025Open Access
P58 Prevention of progression in early fibrosing interstitial lung disease patients: using economic modelling to inform evidence generation
2024
Prevention of progression in early fibrosing interstitial lung disease patients: Using economic modelling to inform evidence generation.
2024
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis
ERJ Open Research·2024· 4 citedOpen Access
Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good
American Journal of Respiratory and Critical Care Medicine·2024Open Access
Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial
ERJ Open Research·2024· 5 citedOpen Access
The American Thoracic Society Research Program: Twenty Years of Driving Discovery in Respiratory Medicine
American Journal of Respiratory and Critical Care Medicine·2024Open Access
Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblasts
Acta Biomaterialia·2024· 19 citedOpen Access
Cardiac Tamponade in ECMO: Infrequent but Important
Journal of Cardiothoracic and Vascular Anesthesia·2024Open Access
IDeT-Sat: A CubeSat Design for Space Debris Detection and Analysis
2024
Fibronectin
Elsevier eBooks·2024· 3 cited
List of contributors
Elsevier eBooks·2024
Lung function trajectories in patients with idiopathic pulmonary fibrosis
Respiratory Research·2023· 22 citedOpen Access
Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblasts
2023Open Access
Primary Human Lung Fibroblasts Alter Collagen Fiber Structure in 3-D Lung Extracellular Matrix-derived Hydrogels in Response to a Fibrotic Microenvironment
2023
page 1 of 15Next →

Frequent Co-authors

Bethany B. Moore(13), Victor J. Thannickal(11), Fernando J. Martínez(11), Kevin R. Flaherty(10), Jeffrey C. Horowitz(8), Galen B. Toews(6), Cory M. Hogaboam(6), Marc Peters‐Golden(6), Thomas H. Sisson(5), Susan Murray(5), Laura E. Niklason(4), Jason R. Spence(4), Carol A. Wilke(4), Andrés F. Muro(4), Steven K. Huang(4), Harold A. Chapman(3), Briana R. Dye(3), Melinda Nagy(3), Rachel Dyal(3), Peter B. Bitterman(3)